News + Resources

Keep up with the latest

Featured

This Scientist Is Building Custom Gene-Editing Tools

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

CRISPR 2.0, the Next Generation

June 21, 2024

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

TEDxBerkeley

The Age of CRISPR: Engineering the Future of Genetic Medicine

February 23, 2024

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

Scrip

Scribe Therapeutics Picks Cholesterol-Lowering As First In Vivo Gene Target

February 7, 2024

All Stories

Press Release

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

Read Now

Press Release

Scribe Therapeutics Presents Data Demonstrating Highly Potent Gene Editing In Vivo, Including Saturated Editing of Hepatocytes in NHPs, by an Engineered XE Genome Editor; Showcases Novel Epigenetic Editing Capabilities at 2024 ASGCT Annual Meeting

May 10, 2024

Read Now

News

DNA: Cutting the Future of Genome Editing

May 2, 2024

The Biomedical Scientist

Read Now

Press Release

DNA: Cutting the Future of Genome Editing

May 2, 2024

The Biomedical Scientist

Read Now

Press Release

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 22, 2024

Read Now

Press Release

Scribe Therapeutics to Present on Advances in CRISPR Genome and Epigenome Editing at the 2024 American Society of Gene & Cell Therapy (ASGCT) Annual Meeting

April 22, 2024

Read Now

News

CRISPR technologies fuelling haematological innovations

April 12, 2024

European Pharmaceutical Review

Read Now

Press Release

CRISPR technologies fuelling haematological innovations

April 12, 2024

European Pharmaceutical Review

Read Now

News

CRISPR drug licensing deals secure $21bn in top three therapy areas over five years

March 28, 2024

Pharmaceutical Technology

Read Now

Press Release

CRISPR drug licensing deals secure $21bn in top three therapy areas over five years

March 28, 2024

Pharmaceutical Technology

Read Now

Press Release

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 6, 2024

Read Now

Press Release

Scribe Therapeutics to Participate in the Leerink Partners Global Biopharma Conference

March 6, 2024

Read Now

News

Future of Epigenetic Medicine

July 22, 2024

FutureBites

Read Now

News

CRISPR 2.0, the Next Generation

June 21, 2024

Aspen Ideas: Health

Read Now

News

CRISPR technology’s next wave: Eight companies to watch in 2024

June 20, 2024

Labiotech

Read Now

News

Top Five Privately Held Gene Editing Therapy Companies

May 31, 2024

Genetic Engineering & Biotechnology News

Read Now

News

Women @ RopesTalk: Conversation with Svetlana Lucas, Scribe Therapeutics

May 22, 2024

Ropes & Gray

Read Now

News

DNA: Cutting the Future of Genome Editing

May 2, 2024

The Biomedical Scientist

Read Now

Press release

Scribe Therapeutics Presents Data on its Epigenetic Long-Term X-Repressor Technology at the 2025 Keystone Symposia on Precision Genome Engineering Conference

March 7, 2025

Read Now

Press release

Scribe Therapeutics to Participate in Upcoming Conferences

February 26, 2025

Read Now

Press release

Scribe Therapeutics Achieves Milestone for In Vivo Program in Collaboration with Sanofi

January 13, 2025

Read Now

Press release

Scribe Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

January 9, 2025

Read Now

Press release

Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024

November 25, 2024

Read Now

Press release

Scribe Therapeutics to Present Preclinical Data on CRISPR Genome and Epigenome Editing Technologies at American Heart Association (AHA) Scientific Sessions 2024

October 30, 2024

Read Now

Publications and presentations

Presentation

Scribe Corporate Deck 2025 Q1

February 3, 2025

Read Now

Publication

CasX enzymes comprise a distinct family of RNA-guided genome editors

February 4, 2019

Nature

Read Now

Publication

Efficient genome editing in the mouse brain by local delivery of engineered Cas9 ribonucleoprotein complexes

May 1, 2017

Nature Biotechnology

Read Now

Publication

Targeted gene knock-in by homology-directed genome editing using Cas9 ribonucleoprotein and AAV donor delivery

March 2, 2017

Nucleic Acids Research

Read Now

Publication

Profiling of engineering hotspots identifies an allosteric CRISPR-Cas9 switch

June 1, 2016

Nature Biotechnology

Read Now

Publication

Multi-reporter selection for the design of active and more specific zinc-finger nucleases for genome editing

January 7, 2016

Nature Communications

Read Now

Publication

Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery

December 15, 2014

eLife

Read Now

Publication

Programmable RNA recognition and cleavage by CRISPR/Cas9

December 11, 2014

Nature

Read Now

Publication

MicroRNA-mediated switching of chromatin-remodelling complexes in neural development

July 30, 2009

Nature

Read Now